Financial Survey: ClearPoint Neuro (NASDAQ:CLPT) & Nuwellis (NASDAQ:NUWE)

ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) and Nuwellis (NASDAQ:NUWE – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Volatility & Risk

ClearPoint Neuro has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for ClearPoint Neuro and Nuwellis, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ClearPoint Neuro 1 0 2 0 2.33
Nuwellis 1 0 0 0 1.00

ClearPoint Neuro presently has a consensus target price of $24.33, suggesting a potential upside of 186.95%. Given ClearPoint Neuro’s stronger consensus rating and higher probable upside, equities research analysts plainly believe ClearPoint Neuro is more favorable than Nuwellis.

Earnings & Valuation

This table compares ClearPoint Neuro and Nuwellis”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ClearPoint Neuro $45.49 million 5.97 -$25.54 million ($1.21) -7.01
Nuwellis $8.27 million 0.32 -$17.52 million ($1,375.43) -0.00

Nuwellis has lower revenue, but higher earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by insiders. Comparatively, 1.6% of Nuwellis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares ClearPoint Neuro and Nuwellis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ClearPoint Neuro -79.43% -170.24% -37.00%
Nuwellis -150.50% -414.75% -152.11%

Summary

ClearPoint Neuro beats Nuwellis on 12 of the 14 factors compared between the two stocks.

About ClearPoint Neuro

(Get Free Report)

ClearPoint Neuro develops technologies used to plan, guide and monitor minimally invasive procedures in the brain and spine. Its product portfolio includes MRI-guided navigation systems and instruments for neurosurgery, including tools for laser ablation and for delivering therapeutics to targeted areas of the central nervous system. The company also works with biotechnology and pharmaceutical partners on the delivery of cell and gene therapies and other biologics to the brain. Its platforms are designed to support accurate placement and monitoring during procedures and in clinical research.

About Nuwellis

(Get Free Report)

Nuwellis, Inc. is a medical device company focused on fluid management therapies for patients with fluid overload. The company develops and commercializes ultrafiltration technologies designed to remove excess salt and fluid from the blood when conventional diuretic therapy may be inadequate or poorly tolerated. Nuwellis’ principal product is the Aquadex system, including the Aquadex FlexFlow system, a compact ultrafiltration platform used in hospital settings. The system is intended for temporary extracorporeal fluid removal in patients with conditions such as fluid overload associated with heart failure, renal dysfunction, and other critical-care needs.

Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.